Martin Förster
A5080195917- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Head and Neck Cancer Studies
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Lung Cancer Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Head and Neck Surgical Oncology
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer therapeutics and mechanisms
- Cancer Diagnosis and Treatment
- Cancer Research and Treatments
- Biochemical and Molecular Research
- Endometrial and Cervical Cancer Treatments
- Immunotherapy and Immune Responses
- Occupational and environmental lung diseases
- Ferroptosis and cancer prognosis
- CAR-T cell therapy research
University College London
2016-2025
University College London Hospitals NHS Foundation Trust
2016-2025
London Cancer
2016-2025
Cancer Research UK
2004-2025
Royal London Hospital
2014-2025
CRUK Lung Cancer Centre of Excellence
2016-2025
University College Hospital
2014-2024
Cancer Institute (WIA)
2019-2024
Friedrich Schiller University Jena
2000-2024
Jena University Hospital
2017-2024
Among patients with non-small-cell lung cancer (NSCLC), data on intratumor heterogeneity and genome evolution have been limited to small retrospective cohorts. We wanted prospectively investigate in relation clinical outcome determine the clonal nature of driver events evolutionary processes early-stage NSCLC.
Immune evasion is a hallmark of cancer. Losing the ability to present neoantigens through human leukocyte antigen (HLA) loss may facilitate immune evasion. However, polymorphic nature locus has precluded accurate HLA copy-number analysis. Here, we heterozygosity in (LOHHLA), computational tool determine allele-specific copy number from sequencing data. Using LOHHLA, find that LOH occurs 40% non-small-cell lung cancers (NSCLCs) and associated with high subclonal neoantigen burden,...
Spatial and temporal dissection of the genomic changes occurring during evolution human non-small cell lung cancer (NSCLC) may help elucidate basis for its dismal prognosis. We sequenced 25 spatially distinct regions from seven operable NSCLCs found evidence branched evolution, with driver mutations arising before after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, associated APOBEC cytidine deaminase activity. Despite...
BackgroundThe incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity standard cisplatin treatment, but no randomised evidence exists efficacy strategy.MethodsWe did open-label controlled phase 3 trial at 32 head and neck centres Ireland, Netherlands, UK, patients aged 18...
Objectives To estimate the impact of COVID-19 pandemic on cancer care services and overall (direct indirect) excess deaths in people with cancer. Methods We employed near real-time weekly data to determine adverse effect services. also used these data, together national death registrations until June 2020 model deaths, background (pre-COVID-19) mortality, Background mortality risks for 24 cancers without COVID-19-relevant comorbidities were obtained from population-based primary cohort...
PURPOSE In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) patients with a tumor proportion score (TPS) ≥ 50% and 1%. We report long-term outcomes, including after 35 cycles/2 years or second-course pembrolizumab. METHODS Of 1,033 randomly assigned (intention to treat), 690 received up of 2 mg/kg (n = 344) 10 346) every 3 weeks, 343 75 mg/m...
TRACERx, a prospective study of patients with primary non-small cell lung cancer, aims to map the genomic landscape cancer by tracking clonal heterogeneity and tumour evolution from diagnosis relapse.
In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. We report 5-year efficacy safety follow-up for study.Patients were randomized to 2 mg/kg or 10 once every 3 weeks 75 mg/m2 up 35 cycles (2 y). Patients who completed treatment subsequently had recurrence could receive second-course 17 (1 Pembrolizumab doses pooled this...
Human papillomavirus positive (HPV+) head and neck squamous cell carcinoma (HNSCC) is an emerging disease, representing a distinct clinical epidemiological entity. Understanding the genetic basis of this specific subtype cancer could allow therapeutic targeting affected pathways for stratified medicine approach.Twenty HPV+ 20 HPV- laser-capture microdissected oropharyngeal carcinomas were used paired-end sequencing hybrid-captured DNA, 3,230 exons in 182 genes often mutated cancer. Copy...
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response. Genomic analyses show no correlation between molecular features and response, whereas ccRCC-specific human endogenous retrovirus expression indirectly correlates clinical T receptor (TCR) analysis reveals significantly higher number expanded TCR...
Lung cancer is the leading cause of cancer-associated mortality worldwide
Abstract B cells are frequently found in the margins of solid tumours as organized follicles ectopic lymphoid organs called tertiary structures (TLS) 1,2 . Although TLS have been to correlate with improved patient survival and response immune checkpoint blockade (ICB), underlying mechanisms this association remain elusive Here we investigate lung-resident cell responses patients from TRACERx 421 (Tracking Non-Small-Cell Lung Cancer Evolution Through Therapy) other lung cancer cohorts, a...
Background: Cancer and multiple non-cancer conditions are considered by the Centers for Disease Control Prevention (CDC) as high risk in COVID-19 emergency. Professional societies have recommended changes cancer service provision to minimize risks patients health care workers. However, we do not know extent which patients, whom multi-morbidity is common, may be at higher overall of mortality a net result factors including infection, services, socioeconomic factors. Methods: We report...
Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity.In phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 400 mg) in patients who had advanced or metastatic solid tumors harbor mutation. The primary objective an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, biomarkers response resistance were also assessed.A total 137 (60 with non-small-cell lung cancer...
Metastatic disease is responsible for the majority of cancer-related deaths
Abstract A 3-year prospective, randomized, placebo-controlled trial of oral clodronate 800 mg showed that the incidence clinical fractures was decreased by 20% in 5596 elderly women unselected for osteoporosis. The effect occurred absence systematic calcium and vitamin D supplementation observed across a wide range BMDs. Introduction: To date, most studies with bisphosphonates have reported on their use individuals selected to be at high risk fracture usually presence low BMD or prior...
Nanometre-scale metal tips irradiated by femtosecond laser pulses represent ultrafast electron sources. The combination of the pulse and tip offers possibility extending attosecond science from atomic or molecular gases to surfaces solid nanoemitters. We first review this emerging research field focusing on rescattering at sharp tips. In particular, we investigate carrier–envelope phase effects that reveal emission dynamics. Furthermore, present detailed theory models support interpretation.